Race Oncology Limited (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Race Oncology Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Race Oncology Limited (ASX: RAC)
Latest News
Share Gainers
Why is the Race Oncology (ASX:RAC) share price up 18% in a month?
Healthcare Shares
What's going on with the Race Oncology (ASX:RAC) share price today?
Share Market News
Race Oncology (ASX:RAC) share price slumps on quarterly update
Healthcare Shares
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
Healthcare Shares
The Race Oncology (ASX:RAC) share price is stumbling today
Share Gainers
Why the Race Oncology (ASX:RAC) share price is charging higher today
Share Gainers
Why Ecofibre, MoneyMe, Nearmap, & Race Oncology shares are storming higher
Healthcare Shares
Here's why the Race Oncology (ASX:RAC) share price is leaping higher
Healthcare Shares
Why the Race Oncology (ASX:RAC) share price is frozen
Share Gainers
Why the Race Oncology (ASX:RAC) share price is racing higher
Share Gainers
Why Ampol, Netwealth, Orocobre, & Race Oncology shares are storming higher
Share Gainers
Why the Race Oncology (ASX:RAC) share price is rocketing 10% higher
Frequently Asked Questions
-
No, Race Oncology does not pay dividends at this time.
-
Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Race Oncology Limited
Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.
Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.
The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).
As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.
